ArticleFrontiers in medicine2026
Clinicopathological features of non-cirrhotic portal fibrosis in primary biliary cholangitis: a 15-year experience at a tertiary referral center.
Article in Frontiers in medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Non-cirrhotic portal fibrosis (NCPF) has been reported to contribute to portal hypertension in primary biliary cholangitis (PBC) preceding the development of cirrhosis. However, the prevalence and clinical significance of NCPF in early PBC remain poorly defined. This study aimed to evaluate the clinicopathological features of NCPF in pre-cirrhotic PBC. Methods: A retrospective analysis was conducted on 92 biopsy-proven pre-cirrhotic PBC patients from a total of 109 cases collected over 15 years. Clinical/serological characteristics and histological features were compared between the PBC-only and PBC + NCPF groups. Results: NCPF was identified in 30/92 (32.6%) pre-cirrhotic PBC patients. Specifically, within the subgroup of 71 patients who had early-stage disease (Scheuer stages 1 and 2), NCPF was present in 20 (28.2%) patients. The PBC + NCPF group was significantly older (54.2 ± 8.5 vs. 49.4 ± 11.4 years, Conclusion: This study identifies a high prevalence of NCPF in early PBC. Its association with greater biochemical activity and specific vascular histopathological alterations suggests that the presence of NCPF may delineate a more active PBC phenotype, offering potential value for early risk assessment.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.